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Carcinoma in situ (CIS) of the breast has increased many-
fold in incidence rates and as a proportion of new breast
cancers following the introduction of mammographic breast
screening. To provide population-based estimatesof invasive
breast cancer risk following CIS, we linked data on 249
incident primary CIS (median age 53 years) to the Cancer
Registry of the Swiss Canton of Vaud (about 600,000 inhabit-
ants) over the period 1977–1994. W omen with concurrent
invasive cancers of the breast were not included. Standard-
ized incidence ratios(SIR) were determined according to the
exact Poisson distribution, with stratification for age and year
of diagnosis. A total of 24 cases of breast cancer vs. 3.4
expected [SIR 5 7.2, 95%confidence interval (CI): 4.6–10.6] ,
and 7 cases of other neoplasms (except non-melanomatous
skin cancer) vs. 6.9 expected (SIR 5 1.0, 95%CI: 0.4–2.1) were
observed. The SIR was10.4 during the first year, 5.6 between
1 and 4 years, and 7.7 after H5 yearsafter CIS diagnosis. SIRs
were consistent in women below and above age 55 years, but
somewhat higher for ductal (SIR 5 8.6) than lobular
(SIR 5 4.2) CIS. Six deathsfrom breast cancer were observed
vs. 1.5 expected (standardized mortality ratio 5 4.0, 95% CI:
1.5–8.7). In 13/19 ductal CIS, but in 2/4 lobular CIS, invasive
cancer occurred in the same breast. In most women, CIS and
subsequent invasive cancer showed the same morphological
(i.e., ductal or lobular) features. The cumulative risk of breast
cancer was16%10 yearsafter CIS diagnosis, emphasizing the
importance of adequate surveillance of women after CIS of
the breast. Int. J. Cancer 77:392–395, 1998.
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Carcinoma in situ (CIS) of the breast has become an increasingly
important disease in North America (Ernster et al., 1996) and
Europe (Levi et al., 1997a) in the last 2 decades. In the early 1990s,
CIS accounted for more than 10–20% of new breast cancer cases
compared to about 3% before the introduction of mammographic
screening (Ernster et al., 1996; Levi et al., 1997a).
CIS includes a spectrum of lesions varying in clinical presenta-
tion, extent, growth pattern, cell type, cytonuclear differentiation
and presence of necrosis (Schnitt et al., 1988). Some may be hard
to distinguish from benign ductal hyperplasia; in others, stromal
invasion cannot be excluded. The traditional classification groups
include two major groups: lobular carcinoma in situ (LCIS) and
ductal carcinoma in situ (DCIS). DCIS, which arises from the
ductal breast epithelium, is often clinically evident as a mass on
physical examination and has a distinctive mammographic finding
(microcalcifications), due to calcium deposition on central ductal
necrosis (Fryckberg et al., 1993).
LCIS, derived from the lobular breast epithelium, is generally
considered to be a marker of increased risk of future malignancy,
rather than the natural precursor of invasive disease (Fryckberg et
al., 1987). It lacks both clinical and mammographic signs and is,
thus, mostly an incidental finding in a breast biopsy performed for
other reasons (Fryckberg et al., 1987).
On account of persisting uncertainty with respect to terminology
(Foucar, 1996) and management (Ernster et al., 1996), relatively
few cohort studies (Betsill et al., 1978; Page et al., 1982, 1995;
Habel et al., 1997) have examined the ability of CIS treated only by
biopsy to evolve to invasion. Herein we provide one of the first
estimates of the risk of invasive breast cancer subsequent to CIS in
a large population-based series coming from the Cancer Registry of
the Swiss Canton of Vaud. Comparison of breast cancer risk with
that of other neoplasms was also made to evaluate the potential
impact of ascertainment bias.
MATERIAL AND METHODS
Data for the present report were abstracted from the Vaud Cancer
Registry file, which includes incident cases of malignant neo-
plasms in the canton (Levi et al., 1997b) whose population,
according to the 1990 census, was about 600,000 inhabitants. The
registry is tumor-based and multiple primaries occurring in one
person are entered separately. Notification is based on a voluntary
agreement between the recording institutions of the canton and the
registry. The main sources of notification, i.e., the Pathology
Department, University of Lausanne, and, since the end of the
1980s, 2 private laboratories, perform over 90% of histological
examinations for the population covered by the registry. Most cases
are registered repeatedly and from different institutions, thus
improving completeness and accuracy of registration. The basic
information available from the register comprises sociodemo-
graphic characteristics of the patient (i.e., age, sex), primary site
and histological type of tumor according to the standard Interna-
tional Classification of Diseases for Oncology (ICD-O) and time of
diagnostic confirmation (histological or clinical diagnosis).
Passive and active follow-up are recorded, and each subsequent
item of information concerning an already registered case is used to
complete the record of the patient. Information from death certifi-
cates is routinely integrated in the data file; cases known only
through death certificates amount to fewer than 5% of the average
number of cases registered per year. Overall histological confirma-
tion exceeds 90%, and is 98% for breast cancer.
Since 1977, a registration scheme, applying the same standard-
ized rules as for incident malignancies, has been implemented for
CIS of the breast. In particular, all histological reports from the
most important pathology laboratories were scrutinized and re-
viewed when reporting diagnosis of CIS. The overall incidence
period considered includes years 1977–1994.
When multiple registrations of CIS were present in the same
woman (n 5 13), only the first was considered. After exclusion of
women with (1) history of previous malignant neoplasm, with the
exception of non-melanomatous skin cancer (n 5 54), and (2)
concurrent cancer of the breast or other sites (n 5 83), our present
series comprised 249 women diagnosed with histologically con-
firmed CIS. They included 186 DCIS (ICD-O M: 8500), 59 LCIS
(ICD-O M: 8520) and 4 CIS of other or unspecified type (Table I).
The age range was 27–87 years (median age 53 years).
Women with CIS were followed up to the end of 1994 for the
occurrence of cancer (excluding non-melanomatous cutaneous
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neoplasms), migration or death. All subsequent invasive breast
cancers were considered new incident neoplasms. Overall, losses to
follow-up were below 3%. A second primary cancer was defined as
a new malignancy occurring in a patient notified as having had a
CIS of the breast, and was classified as independent if so specified
by pathological report (Levi et al., 1997b). Histological confirma-
tion was obtained in all subsequent primaries.
Cumulative risk was computed using the standard life table
approach. Computation of expected numbers was based on site,
age- and calendar year-specific incidence rates multiplied by the
observed number of person-years at risk. The significance of the
observed/expected ratios [standardized incidence ratios (SIR)] and
the corresponding 95% confidence intervals (CI) was based on the
exact Poisson distribution (Breslow and Day, 1987).
RESULTS
Table I gives the distribution of 249 women with CIS of the
breast and the corresponding person-years at risk according to age,
histological type and years since CIS diagnosis. Women with LCIS
were on average younger (median age 50 years) than those with
DCIS (median age 55 years).
Table II gives the observed and expected numbers of invasive
cancer of the breast and other neoplasms in strata of selected
characteristics. Overall, 24 invasive cancers of the breast were
observed vs. 3.4 expected (SIR 5 7.2, 95% CI: 4.6–10.6). The
excess breast cancer risk was persistent, and of similar magnitude,
across various periods since CIS diagnosis, with a SIR of 7.7 found
at 5 years or more after CIS diagnosis. The same held true for age at
CIS diagnosis, SIR being 7.5 below age 55 years and 6.8 at age 55
or more years. DCIS showed a SIR which was higher (8.6, 95% CI:
5.3–13.3), although not significantly, than that for LCIS (4.2, 95%
CI: 1.1–10.7).
Seven cases of cancer other than breast or non-melanomatous
skin cancer were observed vs. 6.9 expected (SIR 5 1.0, 95% CI:
0.4–2.1). These included 1 neoplasm of the oropharynx
(SIR 5 17.2), 1 of the colon/rectum (SIR 5 0.8), 1 of the gallblad-
der (SIR 5 5.8), 2 of the lung (SIR 5 4.0), 1 melanoma of the skin
(SIR 5 2.7) and 1 of the ovary (SIR 5 2.1). In addition, 6 cases of
non-melanomatous skin cancer were observed vs. 3.3 expected
(SIR 5 1.9). None of these estimates was significant. If all cancers,
including breast cancer, were considered together, the excess would
have been of 2.7-fold (95% CI: 1.9–3.8).
Corresponding figures for DCIS in strata of years since diagnosis
and age are given in Table III. No pattern of risk with time since
diagnosis was evident, with SIR of breast cancer of 8.0 in the first
year, 6.5 between 1 and 4 years and 11.7 after $5 years. The SIR of
breast cancer after DCIS was 11.0 in women below age 55 years
and 7.1 in those aged 55 years or over. No meaningful pattern was
observed for other neoplasms or, due to the limited number of cases
diagnosed, for breast cancer after LCIS.
The cumulative risk of invasive breast cancer (including ipsilat-
eral and contralateral breast cancer) at various time intervals
following diagnosis of CIS is shown in Figure 1. The estimated
cumulative risk was 7% after 5, 16% after 10 and 24% after 15
years.
A comparison of the breast side and the histological type of CIS
with that of subsequent invasive cancer of the breast was possible
for 23 women (i.e., all except 1 in whom invasive cancer emerged
as metastatic disease). In 13/19 DCIS, invasive cancer occurred in
the same breast, compared to 2/4 LCIS. Furthermore, in 16 of 19
DCIS, subsequent invasive breast cancer was ductal, while in 3 of 4
LCIS it was lobular. Three DCIS were followed by not otherwise
specified carcinomas of the breast, and one LCIS was followed by a
ductal carcinoma of the other breast.
Finally, 6 deaths from cancer of the breast were found vs. 1.5
expected. The standardized mortality ratio was 4.0 (95% CI:
1.5–8.7), whereas the cumulative risk of death was 4% at 10 and
10% at 15 years.
TABLE I – DISTRIBUTION OF 249 WOMEN WITH CIS OF THE BREAST AND
CORRESPONDING PERSON-YEARS BY AGE, HISTOLOGICAL TYPE AND YEARS
SINCE DIAGNOSIS: VAUD, SWITZERLAND, 1977–94
CIS of the breast
Number Person-years
Age group (years)
20–39 21 162
40–49 79 456
50–59 67 377
60–69 48 278
$70 34 188
Histological type
Ductal 186 968
Lobular 59 456
Other 4 37
Years since diagnosis
,1 — 230
1–4 — 643
5–9 — 403
$10 — 185
Total 249 1,461
TABLE II – OBSERVED (O) AND EXPECTED (E) NUMBERS OF CANCER AND
CORRESPONDING SIRs AND 95% CIs, FOLLOWING 249 CIS OF THE BREAST BY
SELECTED CHARACTERISTICS: VAUD, SWITZERLAND, 1977–1994
Characteristic
Invasive breast cancer Other cancers1
O E SIR (95% CI) O E SIR (95% CI)
Years since diagnosis
,1 5 0.5 10.4 1 0.9 1.1
(3.3–24.2) (0.0–6.1)
1–4 8 1.4 5.6 3 2.9 1.0
(2.4–11.0) (0.2–3.0)
$5 11 1.4 7.7 3 3.1 1.0
(3.8–13.7) (0.2–2.8)
Age at diagnosis (years)
,55 12 1.6 7.5 4 2.3 1.8
(3.9–13.2) (0.5–4.5)
$55 12 1.8 6.8 3 4.7 0.6
(3.5–11.9) (0.1–1.9)
Histological type
Ductal 20 2.3 8.6 5 5.1 1.0
(5.3–13.3) (0.3–2.3)
Lobular 4 1.0 4.2 2 1.7 1.2
(1.1–10.7) (0.1–4.2)
Total 24 3.4 7.2 7 6.9 1.0
(4.6–10.6) (0.4–2.1)
1Non-melanomatous skin cancer excluded.
TABLE III – OBSERVED (O) AND EXPECTED (E) NUMBERS OF CANCERS AND
CORRESPONDING SIRs AND 95% CIs, FOLLOWING 186 DCIS OF THE BREAST BY
SELECTED CHARACTERISTICS: VAUD, SWITZERLAND, 1977–1994
Characteristic
Invasive breast cancer Other cancers1
O E SIR (95% CI) O E SIR (95% CI)
Years since diagnosis
,1 3 0.4 8.0 1 0.8 1.3
(1.6–23.3) (0.0–7.2)
1–4 7 1.1 6.5 2 2.3 0.9
(2.6–13.3) (0.1–3.2)
$5 10 0.9 11.7 2 2.0 1.0
(5.6–21.5) (0.1–3.6)
Age at diagnosis (years)
,55 10 0.9 11.0 2 1.3 1.6
(5.3–20.3) (0.2–5.8)
$55 10 1.4 7.1 3 3.8 0.8
(3.4–13.0) (0.2–2.3)
1Non-melanomatous skin cancer excluded.
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DISCUSSION
Our results show that, after an initial diagnosis of CIS of the
breast, women were at about 7-fold increased risk of developing an
invasive second breast cancer. Such increase was of similar
magnitude in different strata of age and years since CIS diagnosis.
Most data refer to DCIS, but the pattern of risk was similar for
LCIS. A 4-fold excess was found for breast cancer mortality.
A limitation of the present study, which is based on cancer
registration data, is the lack of detailed information on selected
clinicopathological characteristics, such as site and margin status,
which may have relevant prognostic implications (Cheng et al.,
1997). With respect to treatment, a review of pathological reports
available at Vaud Cancer Registry suggested that mastectomy was
performed in 34% of DCIS and 25% of LCIS, indicating that
mastectomy is comparatively low in this population (Ernster et al.,
1996; Habel et al., 1997).
Among the strengths of our study, there are its population basis,
which should render any inference relatively free from selection
bias (Levi et al., 1996), and the complete histological verification
of CIS cases. The absence of excess risk for any of the other cancer
sites is also reassuring with respect to surveillance bias.
Still, diagnosis of CIS of the breast may be more frequent in
women at higher baseline risk of breast cancer. Furthermore, the
issue of exclusion of synchronous neoplasms remains open to
discussion, since the extensive examination of the breast performed
at the time of original diagnosis of CIS may produce a reduction of
subsequent breast cancer risk in these women. These same women,
however, are likely to be subject to increased surveillance of their
breasts, and this could increase the likelihood of a breast neoplasm
being diagnosed. The persistence of risk many years after initial
CIS diagnosis and the absence of any excess for secondary cancer
other than breast weigh, in any case, against the possibility of the
breast cancer excess being due to ascertainment bias.
In our study, the risk of developing breast cancer was similar to
that reported in clinical series of women who did not undergo
mastectomy (Betsill et al., 1978; Fisher et al., 1993; Page et al.,
1982), although higher than in those in whom the entire breast was
removed (Schnitt et al., 1988). In a group of 28 women with DCIS
(Page et al., 1982), 7 evolved as invasive breast cancer within 10
years, and 9 after 30 years, with a risk about 9-fold higher than the
general population. In a randomized comparison of 391 women
treated with lumpectomy and 399 treated with lumpectomy fol-
lowed by radiation therapy, cumulative 5-year incidence was
approximately 12% and 5%, respectively (Fisher et al., 1993).
Such risk is close to (Broet et al., 1995), if not higher than (Levi et
al., 1993), the risk of contralateral second cancer in women with
invasive breast cancer. In a population-based study from western
Washington (Habel et al., 1997), the rate of contralateral invasive
breast cancer was approximately twice the population rate for
DCIS and 3 times the population rate for LCIS. The cumulative
incidence of breast cancer at 10 years was about 6% for DCIS and
8% for LCIS. These estimates are lower than ours, but the
comparison is hampered by the difference in endpoint (contralat-
eral vs. all breast cancer), degree of surveillance and type of
treatment. Largely due to high rates of prophylactic mastectomy, in
fact, Habel et al. (1997) showed extremely elevated rates of second
DCIS in the first follow-up year.
Albeit numbers were limited, our data provide some hints also
on the difference between DCIS and LCIS and the laterality issue
(Page and Jensen, 1996). Little affected by mammographic screen-
ing, LCIS have been excluded in most recent analyses on CIS
(Schnitt et al., 1988; Ernster et al., 1996; Morrow, 1996). Haa-
FIGURE 1 – Cumulative incidence of invasive breast cancer (n 5 24) following 249 CIS of the breast: Vaud, Switzerland, 1977–1994.
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gensen et al. (1978) followed, for an average of 13 years, 209
women with LCIS. Thirty-five breast carcinomas emerged, com-
pared to 5 expected. Cumulative risk was about 7% at 10 years. In
our study, LCIS represented 24% of CIS, occurred at a younger age
and showed an association with subsequent invasive cancer which
appeared somewhat lower than that of DCIS. In agreement with
previous data (Fisher et al., 1993; Webber et al., 1981), however,
DCIS, but not LCIS, tended to be followed more often by
ipsilateral than by contralateral breast cancer.
The close correlation between the presence of ductal or lobular
features in the initial CIS and in the subsequent invasive cancer is
in agreement with the findings of Habel et al. (1997) and supports
the specificity of the 2 lesions. As shown in a review of nearly
120,000 breast cancers from the Surveillance Epidemiology and
End Results Program of the United States (Stalsberg and Thomas,
1993), lobular carcinoma arises from the most steroid hormone-
dependent part of the breast and shows a more marked premeno-
pausal hook than ductal carcinoma. Conversely, about 50% of
DCIS may be estrogen receptor negative (Holland et al., 1997).
The lack of more detailed information on CIS characteristics and
treatment is of major concern. This caution notwithstanding, if,
with the present approach, 15–25% of CIS recur as invasive disease
and 4–10% may die of breast cancer within 10–15 years, adequate
surveillance and clinical management of these lesions are clearly
needed.
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